De novo cis modifier rescues severe SCN8A epilepsy and defines a therapeutic safety corridor

A preprint posted to bioRxiv describes the characterisation of a naturally arising, cis-acting intragenic modifier in mice carrying the Scn8a-N1768D variant — a gain-of-function mutation in the gene encoding the voltage-gated sodium channel NaV1.6 that, in humans, causes developmental and epileptic encephalopathy (DEE) with early-onset, drug-resistant seizures.

Working with a congenic C3H/HeJ.C57BL/6J colony, the authors identified a tightly linked modifier locus (designated L) that arose de novo and segregates independently of the N1768D allele. In N1768D homozygotes carrying L on a 98.4% C3H background, three phenotypic classes emerge: short-lived mice, intermediate survivors, and apparently rescued animals — compared with near-uniform lethality in modifier-absent homozygotes. The modifier acts in cis, meaning it must reside on the same chromosomal copy as N1768D to exert its effect.

The findings carry direct implications for the design of SCN8A therapies. Because both excess and deficit of NaV1.6 are harmful — the authors describe SCN8A as a 'Goldilocks gene' — any therapeutic strategy that reduces channel activity must be calibrated carefully. The modifier study provides in vivo evidence that partial reduction of a gain-of-function allele can shift outcomes across a spectrum from lethality to apparent rescue, but that overshooting into loss-of-function territory remains dangerous.

This work is a preprint and has not yet undergone peer review. The research was conducted in mouse models; applicability to human SCN8A-DEE awaits further investigation. A related peer-reviewed preprint mapping opposing transcriptional programmes in SCN8A gain- and loss-of-function epilepsy was noted in Genetic Current on 11 September 2026.